01—Abstract
Summary
Summary of the 10-K filed February 27, 2008. Cited figures are marked; the original filing is the authoritative source.
IDEXX Laboratories' 2007 10-K shows a company growing revenue 25% to $922.6 milliona, driven by acquisitions (about 8 points of growth) and a 3-point currency tailwind, with organic growth around 14%.
Net income was essentially flat at $94.0 millionb, rising only 0.3%, as operating income grew 6% to $136.2 million. Operating margin fell to 14.8% from 17.3%, reflecting a $10.1 million Navigator® write-down, higher share-based compensation, and the mix shift toward lower-margin laboratory services and instruments. Diluted EPS was $1.46 versus $1.42 in 2006.
The most significant balance-sheet change is leverage. Short-term debt rose to $72.2 millionc under a revolving credit facility used to fund acquisitions (including Vita-Tech, Pourquier, and the Osmetech Critical Care Division) and share repurchases of $118.8 million. Cash and investments fell to $60.4 million, working capital dropped to $82.3 million from $177.5 million, and the company increased its credit facility to $200 million in February 2008.
Operating cash flow was $135.1 milliond, but capital spending is set to climb with roughly $140 million planned for the Westbrook, Maine expansion through 2011. Investors should weigh several risks. Over 40% of revenue is international.
A large pharmaceutical product, about $15.4 million of CAG revenue, could have to be discontinued once FDA approves a competing product or its raw-material inventory runs out in late 2008 or early 2009. Filta-Max® sales of $2.8 million in England and Wales are at risk after 2009.
The Catalyst Dx® launch is expected to shift more VetLab revenue toward instrument sales, which carry lower margins. Management also flagged dependence on Ortho for VetTest® slides and reliance on a few distributors, with Butler Animal Health at 8% of revenue.
02—Key points
Key Highlights
- Revenue grew 24.8% to $922.6M; acquisitions added about 8 points and currency about 3 points, leaving roughly 14% growth on a net basis.
- Net income was nearly flat at $94.0M (+0.3%); diluted EPS rose to $1.46 from $1.42, aided by a 4.7% decline in weighted diluted shares from buybacks.
- Operating margin compressed to 14.8% from 17.3%, driven by a $10.1M Navigator® inventory and royalty write-down, higher share-based compensation, and lower-margin mix.
- Companion Animal Group revenue reached $752.5M (+24%), led by Laboratory & Consulting Services (+36%) and Instruments & Consumables (+19%).
- Leverage increased sharply: short-term revolver debt of $72.2M at year-end, with the facility upsized to $200M in February 2008 to fund acquisitions and buybacks.
- Working capital fell to $82.3M from $177.5M and cash/investments to $60.4M from $96.7M, as the company spent $118.8M on repurchases and $86.6M on acquisitions.
- Key risks include a pharmaceutical product that could be discontinued after an FDA approval for a competitor or when raw-material inventory is depleted in late 2008/early 2009, and Filta-Max® sales at risk after 2009.
03—Questions
Frequently Asked Questions
Why did net income barely grow despite 25% revenue growth?
Operating income rose only 6% because operating expenses grew 30%, faster than gross profit (up 22%). Contributing factors included a $10.1M Navigator® write-down, higher share-based compensation, acquisition-related amortization, and a lower-margin mix from reference labs and instruments. Interest expense also rose to $4.2M from $0.5M, and the effective tax rate increased to 30.3% from 28.4% because 2006 contained several one-time benefits.
How much of the growth came from acquisitions versus organic demand?
Of the 24.8% total revenue growth, about 7.6 points came from businesses acquired since January 2006, mainly veterinary reference labs in Canada and the US, Pourquier in France, and the OPTI Medical business acquired from Osmetech. Currency added about 3.2 points. Excluding both, growth was roughly 14%, which is still strong and driven by higher practice-level sales of slides, SNAP® 4Dx®, and lab testing volume, partly boosted by a March 2007 pet food recall.
What is the main near-term risk to revenue?
A veterinary pharmaceutical product generated $15.4M in 2007 (about 2% of CAG revenue). The FDA would likely require discontinuation within a short period if it approves a competing product, and remaining raw-material inventory is expected to last only until late 2008 or early 2009. IDEXX is seeking approval for a replacement product, but timing and equivalent economics are uncertain. Separately, Filta-Max® sales of $2.8M in England and Wales are expected to be lost starting in 2009 due to a regulatory change.
Is the balance sheet becoming riskier?
Debt increased significantly. The company borrowed $72.2M under its revolving credit facility, which carries rates of LIBOR plus 0.375%-0.875% and a covenant limiting debt to 3x EBITDA. Cash and investments fell to $60.4M, and working capital dropped to $82.3M. Management believes operating cash flow of $135.1M, the $52.8M of available borrowing capacity, and the expanded $200M facility are sufficient for needs, but acquisitions and buybacks increase leverage. Planned Westbrook facility spending of about $140M through 2011 will add further capital demands.
What should investors watch for in 2008?
Key items include the Catalyst Dx® chemistry analyzer launch, which management expects to shift more VetLab revenue toward lower-margin instruments; the SNAPshot Dx® platform launch; the FDA decision on the replacement pharmaceutical product; continued dependence on Ortho for VetTest® slides; and whether the company can sustain high-teens or better lab-services growth while improving margins after the 2007 write-downs and integration costs. The Cyntegra antitrust suit was dismissed in IDEXX's favor, but Cyntegra has appealed.
04—Continue